← SynDRA
LORLATINIB
SynDRA canonical compound SYN0038017 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx |
|---|
| Primary target(s) | ALK | ROS1 |
|---|
| Mechanism of action | ALK tyrosine kinase receptor inhibitor |
|---|
| Indication | non-small cell lung cancer (NSCLC) |
|---|
| Disease area | oncology |
|---|
All known targets
- ALK
- ROS1
- FES
- EGFR
- FER
- FRK
- JAK2
- LTK
- NTRK1
- NTRK2
- NTRK3
- PTK2
Mechanisms of action (all sources)
- ALK INHIBITOR
- ALK tyrosine kinase receptor inhibitor
- ROS1 INHIBITOR
- PTK2 INHIBITOR
- NTRK1 INHIBITOR
- FER INHIBITOR
- TNK2 INHIBITOR
- NTRK2 INHIBITOR
- PTK2B INHIBITOR
- NTRK3 INHIBITOR
- LTK INHIBITOR
- FES INHIBITOR
Drug classes
- Kinase Inhibitors
- Kinase Inhibitor
- Cytochrome P450 2B6 Inducers
- Organic Anion Transporter 3 Inhibitors
- Breast Cancer Resistance Protein Inhibitors
- Cytochrome P450 3A Inducers
- P-Glycoprotein Inducers
- Organic Cation Transporter 1 Inhibitors
- Multidrug and Toxin Extrusion Transporter 1 Inhibitors
ATC classes
- L01E · PROTEIN KINASE INHIBITORS
Cross-references
Synonyms
- lorbrena
- PF-06463922
- PF-6463922
- lorviqua
- Lorbrena
- Lorviqua
- SCHEMBL15274056
- Loratinib
- UNII-OSP71S83EU
- Lorlatinib,PF-06463922
- OSP71S83EU
- lorlantinib
- 4clj
- 4cli
- Lorlatinib [USAN:INN]
- Lorlatinib (JAN/USAN/INN)
- PF06463922(Lorlatinib)
- GTPL7476
- SCHEMBL15261807
- EX-A828
- MolPort-035-789-724
- KS-00000T6C
- 2641AH
- ZINC98208524
- s7536
- MFCD28144520
- BDBM50018830
- AKOS027250753
- DB12130
- CS-39
- PF 06463922
- PF06463922
- CHEMBL3286830
- C21H19FN6O2
- (10R)-7-amino-12-fluoro-10,15,16,17-tetrahydro-2,10,16-trimethyl-15-oxo-2H-4,8-methenopyrazolo[4,3-h][2,5,11]benzoxadiazacyclotetradecine-3-carbonitrile
- (16R)-19-amino-13-fluoro-4,8,16-trimethyl-9-oxo-17-oxa-4,5,8,20-tetrazatetracyclo[16.3.1.02,6.010,15]docosa-1(22),2,5,10(15),11,13,18,20-octaene-3-carbonitrile
- 2H-4,8-Methenopyrazolo(4,3-H)(2,5,11)benzoxadiazacyclotetradecine-3-carbonitrile, 7-amino-12-fluoro-10,15,16,17-tetrahydro-2,10,16-trimethyl-15-oxo-, (10R)-
- (10r)-7-Amino-12-Fluoro-2,10,16-Trimethyl-15-Oxo-10,15,16,17-Tetrahydro-2h-8,4-(Metheno)pyrazolo[4,3-H][2,5,11]benzoxadiazacyclotetradecine-3-Carbonitrile
Reported adverse events
- Arthralgia
- Constipation
- Fatigue
- Headache
- Hypertension
- Myalgia
- Nausea
- Pneumonitis
- Rash
- Back pain
- Bronchitis
- Chest pain
Look up LORLATINIB in the interactive SynDRA portal →